Platinum Industr Q1 FY27 Earnings Call — Analysis (NSE: PLATIND)
Platinum Industries Q1 FY27 was a transition quarter: consolidated revenue fell to ₹108.9 Cr from ₹115.4 Cr YoY and EBITDA margin moderated to 12.34%, while expanded Palghar capacity came online and Egypt commissioning stayed targeted before December 2026.
Result quality: poor — Revenue declined. Management sentiment: cautious.
The take
Q1FY27 Revenue (consolidated) ₹108.9 Cr ( −vs ₹115.4 Cr YoY ) .
Results
Consolidated revenue ₹108.9 Cr vs ₹115.4 Cr YoY; EBITDA ₹13.44 Cr at 12.34% margin vs ₹15.16 Cr and 13.14%; PAT ₹11.13 Cr vs ₹13.07 Cr; standalone revenue grew ~7.3% YoY to ₹110.4 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue (consolidated) | ₹108.9 Cr | −vs ₹115.4 Cr | yoy · Q1FY27 · Q1 FY26 revenue was ₹115.4 Cr |
| EBITDA (consolidated) | ₹13.44 Cr | −vs ₹15.16 Cr | yoy · Q1FY27 · Q1 FY26 EBITDA was ₹15.16 Cr |
| EBITDA margin (consolidated) | 12.34% | −vs 13.14% | yoy · Q1FY27 · Q1 FY26 EBITDA margin was 13.14% |
| Profit before tax (consolidated) | ₹14.95 Cr | −vs ₹17.82 Cr | yoy · Q1FY27 · Q1 FY26 PBT was ₹17.82 Cr |
| Profit after tax (consolidated) | ₹11.13 Cr | −vs ₹13.07 Cr | yoy · Q1FY27 · Q1 FY26 PAT was ₹13.07 Cr |
| EPS (consolidated) | ₹2.03 | none · Q1FY27 · Basic and diluted EPS for Q1 FY27 | |
| Revenue (standalone) | ₹110.4 Cr | +7.3% YoY | yoy · Q1FY27 · Q1 FY26 standalone revenue was ₹102.9 Cr |
| EBITDA (standalone) | ₹12.85 Cr | −vs ₹13.72 Cr | yoy · Q1FY27 · Q1 FY26 standalone EBITDA was ₹13.72 Cr |
| EBITDA margin (standalone) | 11.64% | −vs 13.33% | yoy · Q1FY27 · Q1 FY26 standalone EBITDA margin was 13.33% |
| Profit after tax (standalone) | ₹9.58 Cr | −vs ₹12.52 Cr | yoy · Q1FY27 · Q1 FY26 standalone PAT was ₹12.52 Cr |
| Raw material consumption | ₹78.1 Cr | none · Q1FY27 · Consolidated Q1 FY27 | |
| Employee costs | ₹6.9 Cr | none · Q1FY27 · Consolidated Q1 FY27 | |
| Depreciation | ₹1.8 Cr | none · Q1FY27 · Consolidated Q1 FY27; reflects expanded asset base | |
| Finance costs | ₹0.5 Cr | none · Q1FY27 · Consolidated Q1 FY27 | |
| Unutilized IPO proceeds | ₹45.9 Cr | point_in_time · Q1FY27 · As of 30-Jun-2026; Q1 utilisation ~₹15 Cr; cumulative utilisation ~₹165.9 Cr |
Guidance
Management maintained FY27 revenue growth guidance at 30–40% YoY, down from the earlier 40%, and reiterated Egypt commercial production before 31 December 2026.
Key themes
Capacity ramp-up and product mix transition
Operational commentary
- Palghar expanded facility fully operational: remaining 48,000 tpa PVC, CPVC, lubricants and other capacity commenced commercial production effective 21 May 2026. The expanded facility adds ~60,000 tpa, comprising 24,000 tpa lead-free PVC, 24,000 tpa CPVC and 12,000 tpa lubricants/others.
- India capacity expected to scale towards 85,000+ tpa with full ramp-up, including 6,000 tpa stearates capacity likely commencing commercial production in September/October 2026, delayed from August due to equipment delay.
- Egypt facility on track for commercial production before 31 December 2026, with total investment of ~₹68 Cr and capacity of 60,000 tpa. Management expects duty-free access to the US via Qualified Industrial Zones and free trade access to key South American markets.
- Oleo Chemicals revenue commenced in Q1 FY27 at ~₹5.3 Cr; management is doing seed marketing in India and has exported to Malaysia and Turkey, with manufacturing entry targeted in about one and a half years on already-owned land.
- CPVC additives margin currently ~18%, with management targeting 20–21% by Q4 FY27; margins are being impacted by raw material supply disruptions and higher local sourcing due to shipment issues.
- Competitive positioning: management sees no major CPVC additive competition in India and named Baerlocher, Reagens and Goldstab as the main lead-free PVC additive competitors; CPVC resin capacity build-out by Lubrizol, Reliance and Meghmani is viewed as complementary.
- Rivadu Lifesciences pharma business is still in business-model identification, with some revenue seen from the quarter and collaborations under negotiation.
Analyst Q&A
Q. What is the outlook for pipe demand in July and August?
Krishna Rana said pipe demand saw degrowth last quarter, but has picked up from August and is expected to be good from August until December as PVC prices have stabilized and started moving upward.
Q. Can you break down revenue growth into volume growth, price and mix change, and provide underlying volume growth in stabilizers versus specialty products?
Ashok Bothra said the company generally does not share product volume data and asked the analyst to connect offline for further details.
Q. How much of the EBITDA margin improvement is structural and how much is temporary?
Ashok Bothra said the margin effect was driven by a drastic reduction in other expenses, mainly sales-related expenses because the company did not participate in any exhibition, and by a lesser ECL provision on debtors; he called the impact negligible on EBITDA margins despite lower sales and lower contribution margins.
Q. Do you continue to maintain the 40% revenue growth guidance for FY27?
Krishna Rana said they are waiting to maintain the 40% growth guidance and are on track, but due to war-related demand downside, they will maintain 30–40% growth this year.
Q. What is the status of the metallic soap plant, which was expected to commence in August?
Ashok Bothra said the plant is now expected by September/October because there was some delay in one equipment; stearates sales may not significantly affect revenue growth.
Q. What is the status of the pharma business of Rivadu Lifesciences and what can be expected over the next two to three years?
Research and educational content only. Not investment advice.